Hypertension Screening and Treatment Program
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00007592 |
|
Recruitment Status :
Completed
First Posted : January 1, 2001
Last Update Posted : January 21, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Hypertension | Drug: Chlorthalidone Drug: Furosemide |
Primary Hypothesis: A variety of clinical questions of major importance can be addressed using clinical data routinely obtained in the VA Hypertension Screening and Treatment Program. For example, treatment of mild hypertension reduces the risk of strokes and heart attacks.
Secondary Hypothesis: Target organ damage occurs despite blood pressure control.
Intervention: Chlorthalidone, furosemide, hydrochlorothiazide, metolazone, indapamide, amiloride, spironolactone, triamterene, atenolol, metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol, penbutolol, clonidine, guanethidine, methydopa, prazosin, guanadrel, labetalol, reserpine, guanfacine, hydralazine, minoxidil, captopril, enalapril, lisinopril, diltiazem, nifedipine, verapamil, nicardipine, dyazide, maxzide, pargyline, terazosin, other anti-hypertensives.
Primary Outcomes: Blood Pressure and Target Organ Damage
Study Abstract: Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
This demonstration project provides for central collection of a standard set of clinical data for patients at some of the Hypertension Screening and Treatment Program clinics, thereby setting up a national data base on the treatment of hypertension. The primary objective of this project is to demonstrate the value of establishing this type of database. The database is being used to estimate the average annual cost of different antihypertensive regimens, to determine the cost-efficacy of different therapies and the least expensive effective therapy and to address some major unanswered clinical questions that require large populations and long-term patient care data. There are currently 13 medical centers participating.
| Study Type : | Observational |
| Time Perspective: | Prospective |
| Official Title: | VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY) |
| Study Start Date : | June 1989 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00007592
| United States, California | |
| Vamc - Sepulveda | |
| Sepulveda, California, United States | |
| United States, District of Columbia | |
| Vamc - Washington, Dc | |
| Washington, District of Columbia, United States | |
| United States, Florida | |
| Vamc - Miami | |
| Miami, Florida, United States | |
| United States, Indiana | |
| Vamc - Indianapolis | |
| Indianapolis, Indiana, United States | |
| United States, Iowa | |
| Vamc - Iowa City | |
| Iowa City, Iowa, United States | |
| United States, Mississippi | |
| Vamc - Jackson | |
| Jackson, Mississippi, United States | |
| United States, Ohio | |
| Vamc - Dayton | |
| Dayton, Ohio, United States | |
| United States, Pennsylvania | |
| Vamc - Philadelphia | |
| Philadelphia, Pennsylvania, United States | |
| Vamc - Pittsburgh | |
| Pittsburgh, Pennsylvania, United States | |
| United States, Tennessee | |
| Vamc - Memphis | |
| Memphis, Tennessee, United States | |
| United States, Virginia | |
| Vamc - Richmond | |
| Richmond, Virginia, United States | |
| Puerto Rico | |
| Vamc - San Juan, Pr | |
| San Juan, Puerto Rico | |
| ClinicalTrials.gov Identifier: | NCT00007592 |
| Other Study ID Numbers: |
324 |
| First Posted: | January 1, 2001 Key Record Dates |
| Last Update Posted: | January 21, 2009 |
| Last Verified: | February 2003 |
|
Hypertension national data base on the treatment of hypertension cost of different antihypertensive regimens |
|
Hypertension Vascular Diseases Cardiovascular Diseases Chlorthalidone Furosemide Diuretics Natriuretic Agents |
Physiological Effects of Drugs Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Antihypertensive Agents Sodium Chloride Symporter Inhibitors |